INCRELEX (mecasermin)
INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) AGENTS · PRIMARY INSULIN-LIKE GROWTH FACTOR-1 DEFICIENCY
IPSEN BIOPHARMA
Drug class
Insulin-like Growth Factor-1 (IGF-1) agents
Insulin-like growth factor-1 (IGF-1) agents are recombinant endocrine therapies, primarily represented by mecasermin, designed to replace deficient endogenous IGF-1. Read more about Insulin-like Growth Factor-1 (IGF-1) agents
2 drugs in this class 2 manufacturers
Drugs in Insulin-like Growth Factor-1 (IGF-1) agents
INCRELEX (mecasermin)
INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) AGENTS · PRIMARY INSULIN-LIKE GROWTH FACTOR-1 DEFICIENCY
ETON PHARMACEUT
Filter & compare in the drug finder →
Opens the drug finder with Insulin-like Growth Factor-1 (IGF-1) agents preselected. Add indication or manufacturer filters there.
Insulin-like growth factor-1 (IGF-1) agents are recombinant endocrine therapies, primarily represented by mecasermin, designed to replace deficient endogenous IGF-1.
These agents function as agonists at the type 1 IGF receptor (IGF-1R), activating downstream intracellular signaling pathways that stimulate systemic mitogenesis, chondrocyte proliferation at growth plates, and protein anabolism.
Clinically, they are indicated for the long-term management of severe growth failure in pediatric patients with primary IGF-1 deficiency—such as growth hormone insensitivity syndromes like Laron syndrome—or those with growth hormone gene deletions who have formed neutralizing antibodies to growth hormone therapy.
-
rxlist.com
Insulin-like growth factor-1 (IGF-1) agents are recombinant endocrine therapies, primarily represented by mecasermin, designed to replace deficient endogenous IGF-1 Clinically, they are indicated for the long-term management of severe growth failure in pediatric patients with primary IGF-1 deficiency—such as growth hormone insensitivity syndromes like Laron syndrome—or those with growth hormone gene deletions who have formed neutralizing antibodies to growth hormone therapy
-
drugbank.com
Insulin-like growth factor-1 (IGF-1) agents are recombinant endocrine therapies, primarily represented by mecasermin, designed to replace deficient endogenous IGF-1 These agents function as agonists at the type 1 IGF receptor (IGF-1R), activating downstream intracellular signaling pathways that stimulate systemic mitogenesis, chondrocyte proliferation at growth plates, and protein anabolism
-
patsnap.com
These agents function as agonists at the type 1 IGF receptor (IGF-1R), activating downstream intracellular signaling pathways that stimulate systemic mitogenesis, chondrocyte proliferation at growth plates, and protein anabolism
-
fda.gov
Clinically, they are indicated for the long-term management of severe growth failure in pediatric patients with primary IGF-1 deficiency—such as growth hormone insensitivity syndromes like Laron syndrome—or those with growth hormone gene deletions who have formed neutralizing antibodies to growth hormone therapy
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.